Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- Northwestern University
- Study ID
- NCT01898130
- Phase
- PHASE2
- Status
- Completed
Conditions
- Metastatic Cancer
- Unspecified Adult Solid Tumor, Protocol Specific
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- bevacizumab — BIOLOGICALGiven IV
- quality-of-life assessment — PROCEDUREAncillary studies
Study Details
This is a study to evaluate a drug called bevacizumab in patients with cancer whose disease has spread to their brain. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer. Bevacizumab is a medication and it is thought that bevacizumab may interfere with the growth of new blood vessels; therefore it might stop tumor growth and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels.
Key Dates
- First listed
- Jul 12, 2013
- Start date
- Nov 27, 2013
- Status verified
- Mar 2019
- Primary completion
- Mar 23, 2017
- Completion
- Sep 5, 2018
Study Design
- Enrollment
- 27 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (bevacizumab)Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Objective Radiographic Tumor Response in Patients With Recurrent Solid Tumor Brain Metastases Treated With Bevacizumab [ Time Frame: Every other cycle, starting cycle 3 (1 cycle =28 days) until off study. Range of cycles completed 1-20. ]
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Northwestern University | Chicago | Illinois | 60611 | - |
| Northwestern Memorial Hospital: Lake Forest Hospital | Lake Forest | Illinois | 60045 | - |
| Cadence Health - CDH | Warrenville | Illinois | 60555 | - |
| Columbia University Medical Center | New York | New York | 10032 | - |
Find similar trials in Chicago, IL
Related Studies
- Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic CancersPHASE1 · Recruiting · University of Chicago · Chicago, Illinois
- Optimizing Y90 Therapy for Radiation LobectomyRecruiting · Northwestern University · Jacksonville, Florida
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · Artios Pharma Ltd · Birmingham, Alabama